Top

Published in:

01-12-2013 | Laboratory Investigation

Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study

Authors: Chiara Vasco, Alessandra Canazza, Ambra Rizzo, Adele Mossa, Elena Corsini, Antonio Silvani, Laura Fariselli, Andrea Salmaggi, Emilio Ciusani

Published in: Journal of Neuro-Oncology | Issue 3/2013

Abstract

Glioblastoma multiforme (GBM) is the most aggressive primary human brain tumor. The relatively high amount of T regulatory lymphocytes present in the tumor, contributes to the establishment of an immunosuppressive microenvironment. Samples of peripheral blood were collected from GBM patients and healthy controls and a purified population of Treg (CD4⁺/CD25^bright) was isolated using flow cytometric cell sorting. Treg migrating capacities toward human glioma cell line conditioned medium were evaluated through an in vitro migration test. Our data show that supernatants collected from GBM cell lines were more attractant to Treg when compared to complete standard medium. The addition of an anti-CCL2 antibody to conditioned medium decreased conditioned medium-depending Treg migration, suggesting that CCL2 (also known as Monocyte Chemoattractant Protein, MCP-1) is implicated in the process. The number of circulating CD4⁺/μL or Treg/μL was similar in GBM patients and controls. Specific Treg markers (FOXP3; CD127; Helios; GITR; CTLA4; CD95; CCR2, CCR4; CCR7) were screened in peripheral blood and no differences could be detected between the two populations. These data confirm that the tumor microenvironment is attractive to Treg, which tend to migrate toward the tumor region changing the immunological response. Though we provide evidence that CCL2 is implicated in Treg migration, other factors are needed as well to provide such effect.

Wainwright DA, Nigam P, Thaci B et al (2012) Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 17(2):181–202PubMedCrossRef

Behin A, Hoang-Xuan K, Carpentier AF et al (2003) Primary brain tumors in adults. Lancet 361:323–331PubMedCrossRef

Curtin JF, Candolfi M, Fakhouri TM et al (2008) Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 3(4):e1983PubMedCrossRef

Crane CA, Ahn BJ, Han SJ et al (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 14(5):584–595PubMedCrossRef

Fujimoto S, Greene MI, Sehon AH (1976) Regulation of the immuneresponse to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. J Immunol 116:800–806PubMed

Ha TY, Park HJ, On KK et al (1995) Potentiation of anti-tumor immunity by modulation of suppressor T cells. II. Regression of tumor by modulation of suppressor T cells. Korean J Immunol 17:101–118

Ha TY (2009) The role of regulatory T cells in cancer. Immune Netw 9(6):209–235PubMedCrossRef

Chen X, Oppenheim JJ (2011) Resolving the identity myth: key markers of functional CD4⁺ FoxP3⁺ regulatory T cells. Int Immunopharmacol 11(10):1489–1496PubMedCrossRef

Wang RF (2006) Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Imunopathol 28:17–23CrossRef

10.

Fietta AM, Morosini M, Passadore I et al (2009) Systemic inflammatory response and downmodulation of peripheral CD25⁺ Foxp3⁺ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Human Immunol 70:477–486CrossRef

11.

Liu Z, Kim JH, Falo LD et al (2009) Tumor regulatory T cells potently abrogate antitimor immunity. J Immunol 182:6160–6167PubMedCrossRef

12.

El Andaloussi A, Lesniak MS (2006) An increase in CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells in tumor infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8:234–243PubMedCrossRef

13.

Heimberger AB, Abou-Ghazal M, Reina-Ortiz C et al (2008) Incidence and prognostic impact of FoxP3⁺ regulatory T cells in human gliomas. Clin Cancer Res 14:5166–5172PubMedCrossRef

14.

Jacobs JF, Idema AJ, Bol KF et al (2010) Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 225:195–199PubMedCrossRef

15.

Fecci PE, Mitchell DA, Whitesides JF et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294–3302PubMedCrossRef

16.

Zhang J, Patel L, Pienta KJ (2010) Targeting chemokine (C–C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 95:31–53PubMedCrossRef

17.

Deshmane SL, Kremlev S, Amini S et al (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326PubMedCrossRef

18.

Del Pozo MA, Cabanas C, Montoya MC et al (1997) ICAMs redistributed by chemokines to cellular uropods as a mechanism for recruitment of T lymphocytes. J Cell Biol 137:493–508PubMedCrossRef

19.

Carrillo-de Sauvage MA, Gómez A, Ros CM (2012) CCL2-expressing astrocytes mediate the extravasation of T lymphocytes in the brain. Evidence from patients with glioma and experimental models in vivo. PLoS ONE 7:30762CrossRef

20.

Calatozzolo C, Canazza A, Pollo B et al (2011) Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther 11(242–53):17

21.

Conductier G, Blondeau N, Guyon A et al (2010) The role of monocyte chemoattractant protein CCL2/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93–100PubMedCrossRef

22.

Kim YH, Jung TY, Jung S et al (2012) Tumor-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 26:21–27PubMedCrossRef

23.

Donson AM, Birks DK, Schittone SA et al (2012) Increased immune gene expression and immune cell infiltration in high grade astrocytoma distinguish long-term from short-term survivors. J Immunol 189:1920–1927PubMedCrossRef

24.

Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248(1):156–169PubMedCrossRef

25.

Jordan JT, Sun W, Hussain SF et al (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57(1):123–131PubMedCrossRef

26.

Parney IF, Waldron J, Parsa AT (2009) Flow citometry and in vitro analysis of human glioma associated macrophages. J Neurosurg 110(3):572–582PubMedCrossRef

27.

Lohr J, Ratliff T, Huppertz A et al (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 17(13):4296–4308PubMedCrossRef

28.

de Chaisemartin L, Goc J, Damotte D et al (2011) Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 71(20):6391–6399PubMedCrossRef

29.

Wei S, Kryczek I, Zou W (2006) Regulatory T-cell compartmentalization and trafficking. Blood 108(2):426–431PubMedCrossRef

30.

Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY, Caux C (2012) Innate immune recognition of breast tumor cells mediates CCL2 secretion favoring Treg recruitment within tumorenvironment. Oncoimmunology 1(5):759–761PubMedCrossRef

31.

Weller M (2012) More on the immune privilege of glioblastoma. Neuro Oncol 14(5):527–528PubMedCrossRef

32.

Nalla AK, Gogineni VR, Gupta R et al (2011) Suppression of uPA and uPAR blocks radiation-induced CCL2 mediated recruitment of endothelial cells in meningioma. Cell Signal 23(8):1299–1310PubMedCrossRef

33.

Yan M, Jene N, Byrne D et al (2011) Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 13(2):R47PubMedCrossRef

34.

Wainwright DA, Balyasnikova IV, Chang AL et al (2012) IDO Expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18(22):6110–6121PubMedCrossRef

35.

Coe D, Begom S, Addey C et al (2010) Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59:1367–1377PubMedCrossRef

36.

Cohen AD, Schaer DA, Liu C et al (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5:e10436PubMedCrossRef

37.

Faget J, Bendriss-Vermare N, Gobert M et al (2012) ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4⁺ T cells. Cancer Res 72:6130–6141PubMedCrossRef

Title: Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study
Authors: Chiara Vasco
Alessandra Canazza
Ambra Rizzo
Adele Mossa
Elena Corsini
Antonio Silvani
Laura Fariselli
Andrea Salmaggi
Emilio Ciusani
Publication date: 01-12-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1236-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas

Erratum to: Retrospective analysis of treatment outcome of pediatric ependymomas in Korea: analysis of Korean multi-institutional data

Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Radiosurgery for central neurocytoma: long-term outcome and failure pattern

Cortical hemosiderin is associated with seizures in patients with newly diagnosed malignant brain tumors